htl0039732 capsules
Uterine Cervical Neoplasms
Cancer Research UKPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
25 Active assets in the Uterine Cervical Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC | Phase 3 | BB |
Pembrolizumab GV20 Therapeutics | Phase 3 | BB |
Carboplatin Eli Lilly and Company | Phase 2 | B |
FULVESTRANT Atavistik Bio, Inc | Phase 2 | B |
Pembrolizumab/Vibostolimab Coformulation Merck Sharp & Dohme LLC | Phase 2 | B |
View all 29 →
Same molecule, other indications
htl0039732 capsules is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →